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Inhibitors of the excision reaction catalysed by HIV-1 RT
(reverse transcriptase) represent a promising approach in the fight
against HIV, because these molecules would interfere with the
main mechanism of resistance of this enzyme towards chain-
terminating nucleotides. Only a limited number of compounds
have been demonstrated to inhibit this reaction to date, including
NNRTIs (non-nucleoside RT inhibitors) and certain pyrophos-
phate analogues. We have found previously that 2GP (2-O-gal-
loylpunicalin), an antiviral compound extracted from the leaves
of Terminalia triflora, was able to inhibit both the RT and the
RNase H activities of HIV-1 RT without affecting cell prolifera-
tion or viability. In the present study, we show that 2GP also
inhibited the ATP- and PPi-dependent phosphorolysis catalysed
by wild-type and AZT (3′-azido-3′-deoxythymidine)-resistant en-
zymes at sub-micromolar concentrations. Kinetic and direct-
binding analysis showed that 2GP was a non-competitive inhibitor
against the nucleotide substrate, whereas it competed with the
binding of RT to the template–primer (Kd = 85 nM). As expected
from its mechanism of action, 2GP was active against mutations
conferring resistance to NNRTIs and AZT. The combination of
AZT with 2GP was highly synergistic when tested in the presence
of pyrophosphate, indicating that the inhibition of RT-catalysed
phosphorolysis was responsible for the synergy found. Although
other RT inhibitors that compete with the template–primer
have been described, this is the first demonstration that these
compounds can be used to block the excision of chain terminating
nucleotides, providing a rationale for their combination with nu-
cleoside analogues.
Key words: 3′-azido-3′-deoxythymidine (AZT), combined
chemotherapy, HIV, nucleoside excision, phosphorolysis, reverse
transcriptase.
INTRODUCTION
Combined chemotherapy has dramatically reduced morbidity and
mortality in patients with AIDS [1]. Nowadays the main target
for the treatment of the HIV-1 is the RT (reverse transcriptase). In
fact, 14 of the 24 approved drugs for the treatment of HIV infec-
tion are RT inhibitors [2]. They can be divided into two broad
groups: nucleoside analogues and NNRTIs (non-nucleoside RT
inhibitors) [3,4]. Nucleoside analogues include compounds such
as AZT (3′-azido-3′-deoxythymidine), ddI or ddC, which inhibit
DNA elongation in their triphosphate forms by acting as chain
terminators. On the other hand, NNRTIs inhibit DNA polymeriz-
ation by binding to a hydrophobic pocket close to the active site.
A major concern in HIV chemotherapy is the emergence of
RT variants with reduced susceptibility to anti-retroviral drugs.
This problem is more pronounced with NNRTIs, because a single
mutation in the RT gene can cause cross-resistance against most
of them [3]. For example, RT carrying the Y181C mutation shows
>30-fold resistance to nevirapine and delavirdine and 2- to -3-fold
resistance to efavirenz [5–7]. Resistance to nucleoside analogues
arises in two different ways [8]. Some mutations allow the enzyme
to discriminate between the natural deoxynucleotide and the ana-
logue at the time of incorporation. Other mutations do not affect
the efficiency of incorporation, but increase the ability of the en-
zyme to excise the nucleotide analogue once it is incorporated into
the primer. This is the case for AZT, in which the RTAZT (AZT-
resistant RT) efficiently catalyses the ATP-mediated excision of
AZTMP (AZT-5′-monophosphate) from the terminated primer
[8–10]. Currently the excision mechanism has become the do-
minant mechanism of nucleoside analogue resistance, and it seems
that some mutants of RT are able to excise most nucleoside
analogues with varying efficiencies.
Several strategies to block the excision reaction catalysed by
HIV-1 RT have been proposed [8], but only a limited number of
inhibitors are available to date. We and others have described that
NNRTIs, in addition to blocking DNA polymerization, inhibit
RT-catalysed phosphorolysis [11–13]. Recently, we have also
found that some pyrophosphate analogues inhibit the excision
of chain-terminating nucleotides by competing with ATP or PPi,
whereas RT uses other analogues as substrates for this reaction
[14]. In addition, it has been suggested that compounds that
interfere with the productive binding of ATP and analogues of
the dinucleotide tetraphosphate product of the excision reaction,
may also be suitable for this purpose [8]. Although these are
attractive possibilities, the efficacy of such inhibitors remains to
be proven. For this reason there is a need for new drugs that inhibit
this process.
We have reported previously that aqueous leaf extracts from
Terminalia triflora were active in inhibiting the DNA polymerase
and RNase H activities of HIV-1 RT at concentrations that were
not cytotoxic [15]. The bioassay-guided fractionation of these
extracts lead us to the purification and characterization of 2GP
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(2-O-galloylpunicalin) [16]. This compound inhibited HIV-1 RT
activity and viral replication at sub-micromolar concentrations.
In the present study, we examined the mode of action of this
compound and demonstrate that 2GP also inhibits the excision
reaction catalysed by RT by competing with the template–primer.
Consequently, 2GP synergistically inhibited the wild-type and the
AZT-resistant enzymes when combined with AZT in the presence
of the natural substrates of phosphorolysis. Taken together, these
results provide a rationale for the combination of template–primer
analogues with chain-terminating nucleotides.
EXPERIMENTAL
Enzymes and nucleic acids
Recombinant p66/p51 wild-type RT and RTAZT were expressed
and purified as described previously [12]. RT5mut (RT carrying
mutations D67N, K70R, T215Y, K219Q and Y181C) was
obtained from the plasmid coding for p66-RTAZT (which carries
mutations D67N, K70R, T215Y and K219Q), by changing
the TAT (codon 181) into TGT using a mutagenesis kit from
Stratagene. The corresponding p51 subunit was obtained from
the p66 plasmid by introducing two consecutive stop codons as
described previously [12]. The presence of the mutations was
verified by analysing the complete sequence of the gene. Poly(rA)
and dNTPs were purchased from Amersham Biotech and PAGE-
purified oligonucleotides were obtained from Proligo. In the
following oligonucleotides: d refers to deoxynucleotides and r to
ribonucleotides: r39 template, (5′-AAAAAAAAUAAAAGAA-
CAGGUCGACUCUAGAGGAUCCCC-3′); r36 template, (5′-
AAAAAAAAAAAAAAAGGUCGACUCUAGAGGAUCCCC-
3′); d21 primer, (5′-GGGGATCCTCTAGAGTCGACC-3′).
AZTMP-terminated d21 primer was obtained from d21 and
purified by PAGE as described previously [14].
RT activity
Enzyme activity was measured as described previously [19].
Briefly, RT was incubated in a total volume of 50 µl for 10 min
with the indicated amounts of enzyme, poly(rA)–dT20 and labelled
dTTP in a buffer containing 50 mM Tris/HCl (pH 8.3), 100 mM
KCl, 0.05% Nonidet P-40, 7 mM MgCl2, 2 mM EGTA, and
2 mM DTT (dithiothreitol). Initial rates were determined from the
total radioactivity incorporated into the primer. In experiments
where an excess of enzyme over template–primer were used,
10 nM RT was incubated in buffer A (50 mM Tris/HCl, pH 8.0,
1.25 mM EGTA, 0.5 mM EDTA, 0.05% NP40, and 10 mM
MgCl2) containing 100 mM NaCl with 3 nM of the 5′-32P-labelled
d21 primer annealed to r36 template and 20 µM dTTP in a final
volume of 50 µl. After 60 min, the reactions were quenched by the
addition of an equal volume of loading buffer (90% formamide,
10 mM EDTA, 0.025% Bromophenol Blue and 0.025% Xylene
Cyanol). Samples were analysed by denaturing PAGE using 12%
(w/v) gels containing 7 M urea.
Phosphorolysis assay
d21-AZT annealed to r39 (1 nM of 5′-32P-labelled) was incubated
at 37 ◦C in a final volume of 50 µl with 25 nM RT and the
inhibitor in buffer A containing 100 mM NaCl and 150 µM of
PPi or 3 mM ATP. The reactions containing PPi were incubated
for 60 min and those containing ATP were incubated for 150 min.
After the stated time periods, the reactions were quenched by the
addition of the same volume of loading buffer and the samples
were analysed by denaturing PAGE [18]. Data were fitted by
nonlinear regression to equation: f = 1/[1 + (IC50/D)m], where f
is the fractional inhibition, D represents the concentration (dose)
of the inhibitor, IC50 the concentration of the inhibitor giving
50% of inhibition, and m a parameter giving the sigmoidicity of
the dose–response curve.
In some experiments designed to ascertain the mechanism of
inhibition of RT-catalysed phosphorolysis by 2GP, the inhibitor
was added after the formation of the complex between RT and
r39–d21-AZT. In these experiments, RT was pre-incubated for
5 min either with the inhibitor or with the template–primer prior
starting the reaction. Reactions were then incubated for 2 min in
buffer A containing 20 mM NaCl with 1 nM of 5′-32P-d21-AZT
annealed to r39, 25 nM RT, 2.5 mM PPi, and the indicated amount
of the inhibitor in a final volume of 50 µl.
Filter binding assays
Oligo dT20 was labelled with polynucleotide kinase using [γ -
35S]ATP as substrate and hybridized with poly(rA) [14]. RT
(60 nM) was incubated with 0.5 nM 32P-labelled poly(rA)–dT20
and the indicated amounts of RT inhibitors in binding buffer
(20 mM Tris/HCl, pH 8.0, 50 mM NaCl, 2 mM MgCl2 and 2 mM
DTT). After 30 min of incubation at 37 ◦C, the reactions were
filtered under suction through a Multiscreen nitrocellulose filter
plate (MAHA N45, Millipore) and rinsed with 50 µl of binding
buffer. Under these conditions the filter binds the protein, but
not the template–primer. Radioactivity retained on the filters was
measured by scintillation counting. Apparent dissociation equilib-
rium constants were determined by fitting the data by nonlinear
regression to the equation describing the competitive binding of
a ligand to a single site on the enzyme [17].
Mobility shift assays
The ability of HIV-1 RT to form a stable complex with the
template–primer was assessed by a gel shift assay [14]. For this
purpose the 5′-32P-labelled d21-AZTMP was annealed to the r39
template. The annealed template–primer (4 nM) was incubated for
5 min at 37 ◦C with 2GP and RT, in buffer A containing 20 mM
NaCl. The reaction mixture was placed on ice for 5 min, and the
putative complexes formed were challenged by the addition of
1.5 µM poly(rA)–dT20. After 2 min of incubation, 5 µl of loading
buffer 2 (30% glycerol and 0.025% Bromophenol Blue) was
added, and the complexes that were resistant to this trap were
resolved in a non-denaturing 5% polyacrylamide gel. Apparent
Kd values for 2GP were estimated from the fraction of template–
primer detected in complex in the mobility shift assay as a function
of 2GP concentration. Quantitation of the radioactivity and curve
fitting were performed using ImageMaster software (Amersham-
Pharmacia) and Grafit (Erithacus software) respectively.
Synergy analysis
To measure the combined effect of two inhibitors on RT activity,
25 nM RT was added to a mixture prepared in buffer A containing
100 mM NaCl, 3 nM poly(rA)–dT20, 20 µM [α-33P]dTTP and the
indicated amounts of the inhibitors with or without 250 µM PPi.
Reactions were incubated at 37 ◦C for the indicated periods of time
and quenched by the addition of 5 µl of 0.5 M EDTA. Aliquots
(15 µl) were spotted on to DE81 paper (Whatman), washed three
times with 0.5 M phosphate buffer (pH 7.5), dried and counted.
Synergy analysis was performed both by the Yonetani–Theorell
plot and by calculating the interaction indexes for each combi-
nation as previously described [18,20].
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Figure 1 Inhibition of RT-catalysed phosphorolysis by 2GP
5′-32P-labelled primer (d21-AZTMP; 1 nM) was annealed to the r39 template and incubated in
buffer A containing 100 mM NaCl with 25 nM RT, the indicated amount of 2GP and 150 µM
PPi or 3 mM ATP. The reactions containing PPi were incubated for 60 min and those containing
ATP were incubated for 150 min. Reactions were then quenched and the products analysed by
denaturing PAGE. Under these conditions, no ATP-dependent phosphorolysis was detected for
wild-type RT.
Table 1 Inhibition of PPi and ATP-dependent AZTMP-excision catalysed by
RT and RTAZT
The experiments were carried out as described in the legend for Figure 1. The results are shown
as means +− S.D.
IC50 (µM)
RT RTAZT
Drug PPi PPi ATP
Efavirenz 0.040 +− 0.002 0.020 +− 0.002 0.010 +− 0.001
4-Arylmethylpyridinone 0.010 +− 0.004 0.036 +− 0.01 0.001 +− 0.0001
Nevirapine 2.1 +− 0.15 3.4 +− 0.9 1.7 +− 0.41
9-Cl-TIBO 11 +− 0.54 12 +− 1.4 3.0 +− 0.5
2GP 0.06 +− 0.01 0.088 +− 0.01 0.079 +− 0.01
RESULTS
Inhibition by 2GP of RT-catalysed phosphorolysis
We tested, in the first instance, whether 2GP inhibited the ATP-
and PPi-dependent phosphorolysis catalysed by wild-type RT and
RTAZT. Figure 1 shows that 2GP effectively inhibited the pyrophos-
phorosis catalysed by both enzymes with similar potency. The
amount of 2GP needed for half-inhibition of these reactions
was 0.06 +− 0.01 µM and 0.088 +− 0.01 µM for RT and RTAZT
respectively, showing that the presence of AZT-related mutations
did not affect the activity of this compound. Interestingly, 2GP
inhibited the ATP-mediated excision catalysed by RTAZT in the
same range. Under the same conditions wild-type RT excised
less than 5% of the terminated primer with ATP as substrate,
precluding the accurate determination of inhibition constants. We
have reported previously that some NNRTIs effectively inhibited
the phosphorolysis catalysed by HIV-1 RT. As shown in Table 1,
2GP was as effective as NNRTIs in inhibiting AZTMP excision
from the terminated primer.
Kinetics of inhibition of DNA polymerase activity by 2GP
The ability of 2GP to inhibit the RNase H, DNA polymerase and
phosphorolytic activities of HIV-1 RT lead us to study its mechan-
ism of action. Steady-state kinetics was performed by measuring
the effect of 2GP on RT activity at several concentrations of each
substrate (dNTP or template–primer). Figure 2 shows kinetic data
both in a direct Michaelis–Menten plot and in a double recipro-
cal plot. In the direct plot, all the experimental data were simul-
taneously fitted by nonlinear regression to the three-dimensional
equations defining competitive, non-competitive or uncompetitive
inhibition. The equation that fitted the experimental data best
was plotted. Figure 2(A) shows that 2GP was a linear non-
competitive inhibitor against dTTP in polymerization reactions.
Analysis of the inhibition by 2GP with respect to template–primer
was examined by varying the concentration of poly(rA)–dT20,
while maintaining dTTP at a fixed concentration of 10 µM. As
shown in Figure 2(B), 2GP displayed a competitive inhibition
pattern with respect to poly(rA)–dT20. The calculated competitive
constant was 0.031 +− 0.007 µM.
Effect of 2GP on the binding of HIV-1 RT to the template–primer
In order to verify the competitive nature of the interaction between
2GP and template–primer, we examined whether this compound
interfered with the formation of the RT–template–primer binary
complex in a filter-binding assay. As shown in Figure 3(A),
2GP inhibited the binding of poly(rA)–dT20 to RT in a dose-
responsive manner. The apparent Kd value for the binding of RT
to poly(rA)–dT20 determined from an independent experiment was
0.1 +− 0.02 nM (results not shown). Experimental data were fitted
to the quadratic equation describing the competitive binding of
two ligands, 2GP and poly(rA)–dT20, to a single site [17], resulting
in a Kd (app) for 2GP of 80 +− 6 nM. As a control we measured the
effect of delarvidine (U-90152s) in this assay. This NNRTI did not
affect the binding of template–primer to HIV-1 RT (Figure 3A).
The displacement of the template–primer by 2GP was also con-
firmed in a mobility shift assay. This assay detected the presence
of a stable complex between HIV-1 RT and the AZT-terminated
template–primer. The apparent dissociation constant for the RT–
r39–d21-AZT complex under these conditions was 1.1 +− 0.1 nM.
In the presence of increasing concentrations of 2GP the amount
of template–primer bound to RT was reduced, and eventually
the band corresponding to this complex disappeared (Figure 3B).
These results demonstrate directly that 2GP competes with temp-
late–primer for binding to RT. Quantitation of the intensity of the
band gave a Kd (app) for 2GP of 89 +− 4 nM.
2GP abolishes HIV-1 wild-type and mutant RT activity
It has been demonstrated that a substantial excess of RT over
viral RNA exists in vivo. Therefore complete inhibition of viral
replication would require that RT activity be fully abolished by the
inhibitor, because residual activity of RT would lead to sustained
viral replication and to the rapid emergence of viral resistance.
For this reason, we have measured the effect of several inhibitors
on RT activity using an excess of enzyme over template–primer.
Reactions were incubated for 60 min and the polymerization
products were separated in a polyacrylamide gel. As a control, we
also measured the effect of three structurally unrelated NNRTIs
that inhibited the excision reaction [12]. Table 2 shows that
under these stringent conditions 9-Cl-TIBO and nevirapine were
far less effective than 4-arylmethylpyridinone [3-dimethylamino-
4-(3,5-dimethylbenzyl)-5-ethyl-6-methylpyridin-2(1H)-one] in
inhibiting HIV-1 RT, whereas 2GP retained its activity at sub-
micromolar concentrations. Neither the presence of AZT-related
mutations nor the presence of a fifth mutation (Y181C) affected
the activity of 2GP. However, the presence of the Y181C mutation
conferred high resistance to all NNRTIs tested to RT5mut. The
IC50 for 4-arylmethylpyridinone increased more than 10-fold with
respect to wild-type RT, and the resistance toward nevirapine and
to 9-Cl-TIBO could not be quantitated due to the low activity of
these compounds on RT5mut under these conditions.
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Figure 2 Inhibition of HIV-1 RT-associated DNA polymerase by 2GP
(A) Michaelis–Menten and Lineweaver–Burk plots for the inhibition of RT activity by 2GP with dTTP as the variable substrate. The concentrations of 2GP were 0 (), 0.2 (), 0.5 (), 0.8 () and
2 µM (). In the direct plot, all the experimental data were fitted simultaneously by nonlinear regression to the three-dimensional equation defining non-competitive inhibition, which gave a K i
value of 0.41 +− 0.02 µM. (B) Michaelis–Menten and Lineweaver–Burk plots for the inhibition of RT activity by 2GP with poly(rA)–dT20 as the variable substrate. Concentrations of 2GP were 0 (),
0.05 (), 0.15 () and 0.5 µM (). In this case the best fit corresponds to a competitive inhibition with K ic = 0.031 +− 0.007 µM.
Mechanism of inhibition of phosphorolysis by 2GP
We have found that 2GP showed a competitive pattern against
template–primer in DNA polymerase assays and that this com-
pound interfered with the binding of RT to the template–primer
in direct-binding assays. Although this mechanism may explain
the inhibition of the phosphorolytic activity by 2GP, a direct
relationship between the inhibition of DNA binding and the
inhibition of phosphorolysis was not formally demonstrated. For
this reason, we performed an experiment adding the inhibitor
after the formation of the complex between RT and AZT–DNA
and then examined the phosphorolysis. Under these conditions,
some phosphorolytic activity, corresponding to the pre-formed
RT–template–primer complexes, must be detected before RT
dissociates and binds to an excess of 2GP. This activity must be
absent if the enzyme is pre-incubated in the presence of 2GP. In
these experiments we added millimolar concentrations of PPi
in order to obtain a substantial amount of phosphorolysis before
RT dissociated from the template–primer. As control, we studied
the effect of an excess of unlabelled poly(rA)–dT20 or efavirenz
under the same conditions.
Phosphorolytic activity was detected when RT was pre-incub-
ated with the template–primer before adding an excess of 2GP or
unlabelled template–primer (Figure 4). This activity was absent if
RT was pre-incubated with the inhibitors prior to incubation with
the template–primer. Interestingly, no activity was detected
with efavirenz irrespective of the order of addition, as expected
for a compound that binds to another site on the enzyme. These
results demonstrate clearly that 2GP inhibited phosphorolysis by
competing with the template–primer.
Effect of the combination of 2GP and AZTTP on RT activity
We have reported previously that the synergy found in combin-
ations of AZT with NNRTIs or certain PPi analogues was due to
the inhibition by these compounds of the nucleotide excision
reaction catalysed by HIV-1 RT [12,18]. For this reason, we
analysed the effect of the combination of 2GP with AZTTP on
HIV-1 RT. In the absence of PPi, the combination of 2GP and
AZTTP resulted in parallel lines in a Yonetani–Theorell plot,
indicating that this combination was merely additive (Figure 5A).
Interaction indexes for this combination were close to 1 (1.06,
1.05 and 1.03 at 50, 70 and 95% of inhibition respectively), as
expected for an additive combination.
We also tested the same combination under conditions in which
phosphorolysis can take place. In the presence of 250 µM PPi the
combination of 2GP with AZTTP was highly synergistic as judged
by the Yonetani–Theorell plot, with a − intercept/IC50 value
of 0.24 +− 0.04 (Figure 5B). For synergistic combinations this
parameter takes positive values that decrease as synergy increases
[18,19]. This amount of synergy was similar to that found
under the same conditions for the combinations of AZTTP with
efavirenz (− intercept/IC50 = 0.15 +− 0.02), nevirapine (− inter-
cept/IC50 = 0.17 +− 0.2) or pamidronate (− intercept/IC50 =
0.23 +− 0.13) (results not shown). In addition, synergy increased
by extending the time of incubation. For example, interaction
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Figure 3 Effect of 2GP on the binding of RT to template–primer
(A) Filter binding assay. RT (60 nM) was incubated with 0.5 nM labelled poly(rA)–dT20 and
2GP () or U-90152s (). Reactions were filtered through a Multiscreen nitrocellulose filter
plate, rinsed twice with 50 µl of binding buffer and the radioactivity remaining on the filters was
measured by scintillation counting. (B) Electrophoretic mobility shift assays were carried out
to confirm the competition between 2GP and the template–primer. RT (200 nM) was added to
a mixture containing 4 nM of 5′-32P-labelled d21-AZTMP annealed to the r39 primer and 2GP.
The putative complexes formed were challenged by the addition of 1.5 µM poly(rA)–dT20 and
the complexes resistant to this trap were resolved in a non-denaturing 5 % polyacrilamide gel.
Table 2 Inhibition of DNA polymerization catalysed by wild-type and
resistant RTs using a large excess of enzyme over template–primer
RT (10 nM) was incubated with 3 nM (32P labelled) d21 primer annealed to r36 template, 20 µM
dTTP and the indicated inhibitors. The reactions where stopped after 1 h, and the products
were analysed by denaturing PAGE. Inhibition of RT activity was obtained by densitometric
quantitation in each reaction of all oligonucleotides larger than 35 nucleotides [12].
IC50 (µM)
Inhibitor RT RTAZT RT5mut
4-Arylmethylpyridinone 0.75 +− 0.15 0.50 +− 0.01 6.0 +− 2.4
Nevirapine 30 +− 8 32 +− 8 >50
9-Cl-TIBO >50 >50 >50
2GP 0.20 +− 0.01 0.40 +− 0.05 0.38 +− 0.05
indexes calculated at 50% of inhibition for the combination of
2GP with AZTTP in presence of PPi decreased from 0.62 to 0.42
when the reaction time increased from 20 to 60 min (Figure 5C).
Under these conditions RT-catalysed phosphorolysis severely
reduced the potency of AZTTP as a chain-terminating agent.
DISCUSSION
Inhibition of the ATP- or PPi-dependent phosphorolysis catalysed
by HIV-1 RT is a novel approach to fight against viral resistance to
chain-terminating nucleotides. However, only a few compounds
that are able to inhibit this reaction [12–14]. We have found
previously that 2GP, a natural compound isolated from T. triflora,
inhibited both the DNA polymerase and RNase H activities of
HIV-1 RT. In the present study, we extend our previous observ-
ations by showing that 2GP also inhibits the ATP- and PPi-
dependent excision of chain-terminated primers catalysed by HIV-
Figure 4 Mechanism of inhibition of phosphorolysis by 2GP
5′-32P-labelled primer (d21-AZTMP; 1 nM) annealed to the r39 template was pre-incubated
in the absence of Mg2+ with 25 nM RT in buffer A containing 20 mM NaCl and 2.5 mM PPi.
Reactions were then started by adding 10 mM MgCl2 along with the indicated amounts of
2GP, efavirenz or unlabelled poly(rA)–dT20 (cold T/P). After 2 min, the reactions were stopped
and products analysed by denaturing PAGE. In other tubes, RT was first pre-incubated with
each inhibitor and the reactions were started by adding 10 mM MgCl2 along with the labelled
r39–d21-AZT. The addition of 2GP or poly(rA)–dT20 did not completely inhibit phosphorolysis
if RT was pre-incubated with the substrate, due to the activity of preformed RT template–primer
complexes. c, control reaction carried out in the absence of RT.
1 RT. 2GP was as effective as NNRTIs in inhibiting this activity
and, unlike some PPi analogues, such as phosphonoformate [14],
2GP was able to block the RT-catalysed phosphorolysis fully.
Kinetic studies indicated that 2GP acts by interfering with the
binding of HIV-1 RT to the template–primer. Both the filter
binding and the mobility shift assays demonstrated directly that
2GP binds to the free enzyme with a Kd of approx. 85 nM.
As far as we know, this is the first demonstration that a com-
pound that competes with the template–primer is able to inhibit
phosphorolysis. In fact, there are a number of natural and synthetic
compounds that have been shown to inhibit RT activity either by
competing with the template–primer or by selective binding to the
free enzyme. These include, at least, the carboxanilide derivative
UC-84 [21], indolyl aryl sulfone derivatives [22], KM-1 [17],
KM043 [23], avarol and avarone derivates [24] and toxiuxol [25].
Some of them, such as the KM-1, avarol or the avarone derivates
have also been shown to inhibit the RNase H activity of HIV-1 RT
[17,24]. However, it seems that the potential of these compounds
as inhibitors of the phosphorolytic reaction catalysed by HIV-1
RT has not been recognized.
Compounds that interfere with the binding of template–primer
to the enzyme may represent an interesting alternative to the
NNRTIs for combined chemotherapy. First, because some of
them, such as 2GP, inhibit polymerization and phosphorolysis
in the nanomolar range. The potential of other members of this
family as inhibitors of the nucleotide excision catalysed by HIV-1
RT has not been analysed, although, given their mechanism of
action, we anticipate that molecules such as KM-1 [17] will
be effective in blocking RT-catalysed phosphorolysis. Secondly,
because the activity of compounds that interfere with the binding
of RT to the template–primer is not affected by mutations that
confer severe resistance to NNRTIs. Often a single mutation in the
RT may cause resistance to a variety of NNRTIs, precluding
the inhibition of both the polymerase and the phosphorolytic activ-
ities. As expected, 2GP or KM-1 activity is neither affected by
TAM or Y181C mutations [17]. Lastly, because some of these
compounds inhibit HIV-1 RT and viral replication at concen-
trations that do not affect cell proliferation or viability. For
example, 2GP inhibits viral replication with an EC50 of 0.21 µM,
but does not affect cell proliferation of viability below 40 µM
[16]. This profile it is not general to other members of this family,
since some of them exhibit high cytotoxicity in vitro precluding
their therapeutic application [23,25]. It cannot be discarded that
some of these compounds may have alternative modes of action
c© 2007 Biochemical Society
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Figure 5 Effect of the combination of 2GP with AZTTP on HIV-1 RT activity
(A) Effect of the combination in the absence of PPi or ATP. RT (25 nM) was incubated with 2GP and
AZTTP in a buffer containing 3 nM poly(rA)–dT20 and 20 µM [α-33P]dTTP. The concentrations
of AZTTP were 0 (), 0.0125 (), 0.025 (), 0.05 () and 0.1 µM (). Parallel lines in
the Yonetani–Theorell plot indicate that this combination showed mutually exclusive effects.
(B) Effect of the same combination in the presence of 250 µM PPi. Concentrations of AZTTP
were 0 (), 0.025 (), 0.05 (), 0.1 () and 0.2 µM (). Lines converging at the left-hand
side of the y-axis show that this combination synergistically inhibited HIV-1 RT. (C) Interaction
indexes for the combination of AZT with 2GP. AZTTP and 2GP were combined at fixed molar ratios
and assayed on RT as before without (open symbols) or with 250 µM PPi (closed symbols).
Reactions were incubated for 20 min (circles) or 60 min (squares) at 30◦C.
in cell-based assays, such as in the inhibition of the viral binding
to the cell surface [26]. Moreover, several analogues of the
template–primer are either charged or have hydrophilic nature
and their bioavailability should probably be improved before their
therapeutic potential can be fully exploited. However, the high
potency of these compounds as RT inhibitors, some of them
in the nanomolar range, their lack of cross-resistance with
NNRTIs or nucleoside analogues and their potential for combined
chemotherapy merits further development.
The results obtained in the present study provide a rationale
for combining molecules that block the binding of the template–
primer to RT with nucleoside analogues. Combinations of 2GP
with AZTTP were highly synergistic on HIV-1 RT when tested in
the presence of ATP or PPi. In fact, the amount of synergy obtained
for the combination of 2GP and AZTTP was similar to those
found for combinations of AZTTP with NNRTIs. We have shown
previously that the inhibition of RT-catalysed phosphorolysis
seems to be related to the superior long-term efficacy of combin-
ations containing an NNRTI over combinations containing only
nucleoside analogues [12]. Taken together, these results support
the notion that compounds that inhibit the formation of the RT–
DNA complex may be useful in combined chemotherapy with
nucleoside analogues by interfering with the main mechanism of
resistance of this enzyme to chain-terminating nucleotides.
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